Vera Therapeutics, Inc , a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the appointments of two industry veterans to help lead the development of the company’s drug programs .The company has appointed Robert M Brenner as Chief Medical Officer to succeed Dr Celia Lin and William D Turner as Chief Development Officer, effective immediately.